Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

This study tests whether combining tislelizumab (an immunotherapy drug that helps the immune system fight cancer) with Huaier Granule (a traditional Chinese herbal medicine) works better than tislelizumab alone as a first-line treatment for liver cancer (hepatocellular carcinoma) that cannot be surgically removed. **You may be eligible if...** - You are 18 or older - You have confirmed liver cancer (hepatocellular carcinoma or HCC) at an advanced or intermediate stage not suitable for surgery or local treatment - You have not received any prior systemic (whole-body) therapy for liver cancer - You have at least one measurable tumor by imaging - Your liver function is good (Child-Pugh class A) - Your overall health is adequate (ECOG 0 or 1) **You may NOT be eligible if...** - Your cancer involves a blood clot in the main portal vein or inferior vena cava - You have a rare type of liver cancer (fibrolamellar, sarcomatoid, or mixed with bile duct cancer) - You have recently had local liver treatments or immunotherapy (within 28 days) - You have active autoimmune disease requiring immune-suppressing therapy - You have had significant bleeding from varices (enlarged veins in the esophagus or stomach) within 6 months - You are breastfeeding Talk to your doctor to see if this trial is right for you.